Alkermes
Business Services · Ireland · 2,100 Employees
View Company Info for Free
About
Headquarters
Connaught House 1 Burlington Rd, Dublin, Dublin...Phone Number
+353 17728000Website
www.alkermes.comRevenue
$1.5 BillionStock Symbol
ALKSIndustry
Most Recent Scoops
Highlights
$251.2M
Total Funding Amount
-
Most Recent Funding Amount
3
Number of Funding Rounds
Who is Alkermes
Alkermes Org Chart
Is Alkermes your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Alkermes had a recent Job posting/layoffs
Check if Alkermes has recently received funding, and reach out quickly before it becomes old news!
Alkermes, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Alkermes recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Alkermes
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Alkermes launches new products
Check out if Alkermes is spiking on competitors!
Funding: Get notified immidiatlly once Alkermes has new funding data
Recommended Actions
Reach out to Masked Content who joined Alkermes as Masked Content
Find more new buyers
Compare Similar Companies to Alkermes
Compare insights from companies similar to Alkermes, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Compare CEO
How does Richard Pops compare against Competing Companies' CEOs?
Chairman & Chief Executive Officer at Alkerme...
CEO effectiveness to drive business results
VS.
Tassos Gianakakos
CEO at MyoKardia
CEO effectiveness to drive business results
Alkermes financials insights
Gather financial insights about Alkermes, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Alkermes Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Alkermes Tech Stack
Most Recent Scoops
Alkermes News & Media
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN, Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare Conference Date/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT) Jefferies London Healthcare Conference...Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
– 12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy – – Results Presented From Real-World Retrospective Study of Healthcare Resource Utilization and Treatment Patterns in Patients With Schizophrenia or Bipolar I Disorder Following Initiation of...Alkermes plc Reports Third Quarter 2024 Financial Results
— Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024...Alkermes to Report Third Quarter Financial Results on October 24, 2024
DUBLIN, Oct. 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, Oct. 24, 2024 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be...
Frequently Asked Questions Regarding Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophreni... Read More